For Researchers:


The Salgi Esophageal Cancer Research Foundation funds research in the areas of prevention, early detection, screening, and treatment of esophageal cancer.   Grants will be distributed based on the following application process.  All applicants must follow the application process and must meet all deadlines to be considered.

Grants will only be made to nonprofit organizations in the United States of America with certification as tax exempt under Sections 501(c)(3). Organizations that have completed and filed Form 1023 but not yet received an IRS determination letter are not eligible to apply. The Salgi Esophageal Cancer Research Foundation will not consider any of the following for funding:

  • Capital campaigns/ projects;
  • Student research projects;
  • General/indirect/salary/administrative costs;
  • Political lobbying or legislative activities;
  • Annual funds, galas or other special-event fundraising activities;
  • Institutions that discriminate on the basis of race, creed, gender or sexual orientation;
  • Loans, scholarships, fellowships or grants to individuals.

To receive an application, please email us at: salgifoundation at  Include your name, email and the medical/research facility that will be conducting the research, with the subject: “Salgi Research Funding.”  Any and all questions must be submitted through email only:  salgifoundation at with the subject: “Salgi Research Funding.”

Esophageal Cancer Research Funding Awarded:


The Salgi Esophageal Cancer Research Foundation has funded esophageal cancer research for the second time in less than seven years since our charity was founded.  In November, 2018, The Salgi Esophageal Cancer Research Foundation awarded principal investigator, Dr. Donald Low and Virginia Mason Medical Center, grant funding.  Dr. George Hanna of St Mary’s Hospital (Imperial College London) is co-investigator.  As of 2022, this research is currently underway.

The research intends to establish a non-invasive test for the detection of esophageal cancer that is based upon the unique signature of volatile organic compounds (VOCs) within exhaled breath and to analyze exhaled VOCs in response to therapeutic intervention in patients.

With over a 733% increase in the past four decades, esophageal cancer is among the fastest growing and deadliest cancers in the United States and the western world.  There are no current standard or routine screenings to detect esophageal cancer in its earlier stages. Current guidelines recommend referral for endoscopy “only in the setting of ‘red flag’ symptoms that are frequently associated with inoperable disease,” Dr. Low stated.

These ‘red flag’ symptoms, such as difficulty swallowing, chronic cough and GERD, typically appear once the cancer has become advanced.  This, in addition with other factors, leads to the current overall five-year survival rate of only 19.2%. Despite its rapid increase and poor prognosis, esophageal cancer receives very little awareness and research funding.

Read more: 


The Salgi Esophageal Cancer Research Foundation awarded its first grant for esophageal cancer research in July 2015.  The charity awarded program director, Dr. Carlos Minacapelli and Rutgers Robert Wood Johnston Medical School grant funding.

The American Gastroenterological Association (AGA) Institute Council accepted Dr. Minacapelli’s abstract to be presented as a poster presentation during Digestive Disease Week (DDW) 2017 held in Chicago, IL.   The abstract is entitled “Effect of Benzo[a]pyrene along with Acid and Bile is highly carcinogenic as shown in the in-vitro Barrett’s Esophagus Carcinogenesis (BEC) model.”

Esophageal Cancer Research is Critically Underfunded:

Esophageal cancer (adenocarcinoma) is considered one of the fastest growing and deadliest cancers in the United States, according to the National Cancer Institute.  Esophageal cancer (EAC) has increased over 733% in the past four decades.

Despite its rapid increase and poor prognosis, esophageal cancer research receives inadequate private and/or government funding.

The National Cancer Institute spends, on average, only half of one percent for esophageal cancer research from it’s total budget.  In 2017, NCI allocated $31,843,910 for esophageal cancer research funding out of it’s total $5,636.4 billion budget.  In 2018, the NCI received an increase for their total budget by 5%, or $284 million from the previous fiscal year.  However, in 2018, NCI again decreased its investment in research of esophageal cancer to $29,804,836.

Latest Figures From NCI:

-2018 NCI funded Esophageal Cancer Research: $29,804,836
-2018 NCI Total Budget for Cancer Research: $5,927.7 billion budget.

(Source: National Cancer Institute)

The American Cancer Society also decreased for esophageal cancer research projects.

August 2021: 8 for esophageal cancer research out of their total of 739 cancer research grants.
October 2020: 9 for esophageal cancer research out of their total 737 cancer research grants.

While rates have dropped for other cancer types, esophageal cancer rates are skyrocketing!

Donate to Esophageal Cancer Research Today:

There is a dire need for funding for esophageal cancer research.   We believe that funding should be provided for innovative research projects which are aimed at improving current and discovering new diagnosis testing and treatment options

Combined with our other efforts in raising awareness and advocating for standard and routine early detection screenings, incidence and mortality rates will decrease.

Support esophageal cancer research by making a one-time or recurring, tax-deductible donation.


Comments are closed.

%d bloggers like this: